About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Promising Therapy for Patients With Refractory Primary Mediastinal B-cell Lymphoma

by Dr. Trupti Shirole on December 6, 2016 at 5:46 PM
Font : A-A+

 Promising Therapy for Patients With Refractory Primary Mediastinal B-cell Lymphoma

Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer cells. This allows for an improved precision medicine approach to treating cancer.

Moffitt Cancer Center physician-scientist Fredrick L. Locke, will present interim results from cohort 2 of the phase 2 portion of the ZUMA-1 study, which uses CAR-T therapy for patients with refractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma, during the American Society of Hematology Annual Meeting in San Diego.

Advertisement


The ZUMA-1 study utilizes KTE-C19 which is an autologous chimeric antigen receptor (CAR) T cell therapy. During KTE-C19 CAR-T therapy, T cells are isolated from a patient's blood and genetically engineered in Kite's laboratory to target the CD19 protein that is found on lymphoma cells. The genetically engineered T cells are then infused within the patient that they were originally harvested from. The KTE-C19 T cells are able to recognize cancerous lymphoma cells that express CD19 and target them for destruction.

The phase 1 portion of the ZUMA-1study revealed that KTE-C19 was tolerable and produced ongoing remissions in B-cell non-Hodgkin lymphoma patients (Locke et al, Abstr. 1048O, ESMO Congress 2016). The phase 2 portion of the study consists of two cohorts: cohort 1 for patients with chemo-refractory Diffuse Large B cell Lymphoma; and cohort 2 for patients with chemo-refractory primary mediastinal B-cell lymphoma or transformed follicular lymphoma.
Advertisement

As of June 16, six patients with refractory primary mediastinal B-cell lymphoma or transformed follicular lymphoma were treated in cohort 2 with KTE-C19. The patients were highly refractory to prior treatments and included three patients who were refractory to second-line or greater therapy and three patients who relapsed after autologous stem cell transplants.

KTE-C19 therapy resulted in promising clinical activity in these patients. With a median follow-up period of 3.2 months, all six patients achieved a complete remission. KTE-C19 treatment also resulted in manageable toxicities that were generally reversible. Grade 3 treatment-emergent adverse events occurred in 17% of patients and grade 4 treatment-emergent adverse events occurred in 67% of patients. All six patients experienced cytokine release syndrome; however, all cases were grade 1 or 2. Neurotoxicity occurred in 67% of patients and 33% of the cases were grade 3.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
H1N1 Influenza Prevention in Children: What Parents Need to Know
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chronic Lymphocytic Leukemia Reiki and Pranic Healing AIDS-HIV-Cancer Bone Marrow Transplantation Burkitt’s Lymphoma 

Most Popular on Medindia

Sanatogen Vent Forte (Theophylline) Drug Side Effects Calculator Find a Hospital Noscaphene (Noscapine) Diaphragmatic Hernia Accident and Trauma Care Blood - Sugar Chart Color Blindness Calculator Iron Intake Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Promising Therapy for Patients With Refractory Primary Mediastinal B-cell Lymphoma Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests